FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890372607> ?p ?o ?g. }

• W2890372607 abstract "<h3>Background</h3> Methotrexate inhibits the metabolism of purines resulting in the accumulation of adenosine; it also inhibits the activation of T cells and suppresses the expression of intercellular adhesion molecules for T cells. Side effects may show up during the treatment and among them there is hepatic toxicity, characterised by an increase of AST and ALT; such increase is usually asymptomatic but it may lead to a suspension of the treatment. Metadoxine (MTDX) is a drug which is used in order to treat both acute and chronic alcohol intoxication; it also prevents the inactivation of ATP from acetaldehyde and pyroglutamic acid. MTDX also showed to improve hepatic function markers and to decrease oxidative stress leading to a protective effect against radicals. <h3>Objectives</h3> The aim of this preliminary study was to evaluate the possible effect of MTDX on hepatic function in patients affected by RA in therapy with MTX. <h3>Methods</h3> The study involved the recruitment of patients affected by RA in treatment with MTX; a following random selection of a subgroup of patients who took MTDX (500 mg twice a day for 28 days, from the 5th to the 8th week of therapy with MTX) was performed. All the patients underwent a 12-week-follow up in which these parameters were evaluated: demographics, blood tests required for MTX in accordance with datasheets (especially AST and ALT), CRP, ESR, ACPA, numbers of swollen and tender joints, concomitant medications (NSAIDs and steroids) and the degree of disability (HAQ, table 1). <h3>Results</h3> 24 patients affected by RA (20 women), with an mean age of 51.3 years (±14.1) and mean MTX dose of 12.3±2.6, were recruited. 70.3% took GC with a medium dosage (3.72±2.71). Among these 24, 13 patients were underwent MDTX 500 mg twice a day from the 5th to the 8th week. Patients treated with MTDX+MTX showed a significant decrease of hepatic markers (AST Δ−18.38 p=0.004 – ALT Δ−19.23 p=0.004) compare with patients with MTX only (AST Δ−4.27 p=0.110 – ALT Δ−6.09 p=0.045) after a 12-week-monitoring, with no statistically significant difference concerning disease activity (table 2). <h3>Conclusions</h3> This study showed the possible effect of MTDX in increasing the tolerance to the MTX without affecting its effectiveness. Its role may indeed have useful implications in patients who start the therapy with MTX or in those who develop hepatic toxicity during the treatment. <h3>Reference</h3> [1] Fehér J, et al. The Beneficial Effect of Metadoxine in the Treatment of Fatty Liver Diseases. Reviews2009;3(1):65–79. <h3>Disclosure of Interest</h3> None declared" @default.
• W2890372607 created "2018-09-27" @default.
• W2890372607 creator A5012554927 @default.
• W2890372607 creator A5025745099 @default.
• W2890372607 creator A5052431264 @default.
• W2890372607 creator A5077787115 @default.
• W2890372607 creator A5081902640 @default.
• W2890372607 date "2018-06-01" @default.
• W2890372607 modified "2023-09-24" @default.
• W2890372607 title "AB0499 Evaluation of the effectiveness of metaxodine in the hepatic toxicity due to methotrexate in patients with rheumatoid arthritis" @default.
• W2890372607 doi "https://doi.org/10.1136/annrheumdis-2018-eular.6253" @default.
• W2890372607 hasPublicationYear "2018" @default.
• W2890372607 type Work @default.
• W2890372607 sameAs 2890372607 @default.
• W2890372607 citedByCount "0" @default.
• W2890372607 crossrefType "proceedings-article" @default.
• W2890372607 hasAuthorship W2890372607A5012554927 @default.
• W2890372607 hasAuthorship W2890372607A5025745099 @default.
• W2890372607 hasAuthorship W2890372607A5052431264 @default.
• W2890372607 hasAuthorship W2890372607A5077787115 @default.
• W2890372607 hasAuthorship W2890372607A5081902640 @default.
• W2890372607 hasBestOaLocation W28903726071 @default.
• W2890372607 hasConcept C126322002 @default.
• W2890372607 hasConcept C2776151105 @default.
• W2890372607 hasConcept C2777575956 @default.
• W2890372607 hasConcept C2777910003 @default.
• W2890372607 hasConcept C2779384505 @default.
• W2890372607 hasConcept C2781059491 @default.
• W2890372607 hasConcept C29730261 @default.
• W2890372607 hasConcept C2992208098 @default.
• W2890372607 hasConcept C71924100 @default.
• W2890372607 hasConcept C90924648 @default.
• W2890372607 hasConcept C98274493 @default.
• W2890372607 hasConceptScore W2890372607C126322002 @default.
• W2890372607 hasConceptScore W2890372607C2776151105 @default.
• W2890372607 hasConceptScore W2890372607C2777575956 @default.
• W2890372607 hasConceptScore W2890372607C2777910003 @default.
• W2890372607 hasConceptScore W2890372607C2779384505 @default.
• W2890372607 hasConceptScore W2890372607C2781059491 @default.
• W2890372607 hasConceptScore W2890372607C29730261 @default.
• W2890372607 hasConceptScore W2890372607C2992208098 @default.
• W2890372607 hasConceptScore W2890372607C71924100 @default.
• W2890372607 hasConceptScore W2890372607C90924648 @default.
• W2890372607 hasConceptScore W2890372607C98274493 @default.
• W2890372607 hasLocation W28903726071 @default.
• W2890372607 hasLocation W28903726072 @default.
• W2890372607 hasOpenAccess W2890372607 @default.
• W2890372607 hasPrimaryLocation W28903726071 @default.
• W2890372607 hasRelatedWork W1977601919 @default.
• W2890372607 hasRelatedWork W2016284731 @default.
• W2890372607 hasRelatedWork W2034677099 @default.
• W2890372607 hasRelatedWork W2071430138 @default.
• W2890372607 hasRelatedWork W2138814539 @default.
• W2890372607 hasRelatedWork W2143143301 @default.
• W2890372607 hasRelatedWork W2361902531 @default.
• W2890372607 hasRelatedWork W4243626754 @default.
• W2890372607 hasRelatedWork W4256594459 @default.
• W2890372607 hasRelatedWork W4312127714 @default.
• W2890372607 isParatext "false" @default.
• W2890372607 isRetracted "false" @default.
• W2890372607 magId "2890372607" @default.
• W2890372607 workType "article" @default.